4-(3-氯苯基)-2H-吡唑-3-胺 | 95750-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(3-氯苯基)-2H-吡唑-3-胺
• 中文别名: [4-(3-氯苯基)-2H-吡唑-3-基]胺
• 英文名称: 3-Amino-4-(m-chlor-phenyl)-pyrazol
• 英文别名: 4-(3-chloro-phenyl)-1(2)H-pyrazol-3-ylamine；4-(3-chlorophenyl)-1H-pyrazol-5-amine
• CAS: 95750-97-3
• 化学式: C₉H₈ClN₃
• mdl: MFCD07367225
• 分子量: 193.636
• InChiKey: AKBOVXXJALCPNM-UHFFFAOYSA-N

物化性质

• 沸点：
  423.8±35.0 °C(Predicted)
• 密度：
  1.378±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(3-Chlorophenyl)-1h-pyrazol-3-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(3-Chlorophenyl)-1h-pyrazol-3-amine
CAS number: 95750-97-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8ClN3
Molecular weight: 193.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(3-氯苯基)-2H-吡唑-3-胺 在 高氯酸 、 双(三甲基硅烷基)氨基钾 、 对甲苯磺酸 、 三氯氧磷 作用下， 以 四氢呋喃 、 5,5-dimethyl-1,3-cyclohexadiene 、 二氯甲烷 、 甲苯 为溶剂， 反应 6.0h， 生成 methyl 2-tert-butoxy-2-(7-chloro-3-(3-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate
  参考文献：
  名称：

  Inhibitors of Human Immunodeficiency Virus Replication

  摘要：

  该披露通常涉及到式I的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。

  公开号：

  US20130231331A1
• 作为产物：
  描述：

  间氯氰苄 在 乙醇 、 sodium 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 19.0h， 生成 4-(3-氯苯基)-2H-吡唑-3-胺
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

  摘要：

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。

  公开号：

  US20120277224A1

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。
• Synthesis and biological evaluation of novel pyrazolo[1,5-a]pyrimidines: Discovery of a selective inhibitor of JAK1 JH2 pseudokinase and VPS34
  作者：Justin D. Singleton、Reuben Dass、Nathaniel R. Neubert、Rachel M. Smith、Zak Webber、Marc D.H. Hansen、Matt A. Peterson

  DOI：10.1016/j.bmcl.2019.126813

  日期：2020.1

  A series of novel 3,6-di-substituted or 3-substituted pyrazolo[1,5-a]pyrimidines were prepared via a microwave-assisted approach that generated a broad array of derivatives in good yields (20-93%, ave. = 59%). The straightforward synthesis involved sequential treatment of commercially-available acetonitrile derivatives with DMF-dimethylacetal (120 °C, 20 min), followed by treatment with NH2NH2·HBr

  通过微波辅助方法制备了一系列新颖的3,6-二取代或3-取代的吡唑并[1,5-a]嘧啶，该方法以良好的收率（20-93％ave）产生了广泛的衍生物。 = 59％）。简单的合成方法包括依次用DMF-二甲基乙缩醛（120°C，20分钟）处理市售的乙腈衍生物，然后用NH2NH2·HBr（120°C，20分钟）和1,1,3,3-处理四甲氧基丙烷或2-芳基取代的丙二醛（120°C，20分钟）。在体外筛选化合物针对MCF7乳腺癌和/或A2780卵巢癌细胞系的抗有丝分裂活性。活性最高的化合物的EC50值为0.5至4.3μM，
• Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
  申请人：Xu Yong

  公开号：US09416132B2

  公开（公告）日：2016-08-16

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一的蛋白激酶（I）、（II）或（III）：或其立体异构体、前药、互变异构体或药用可接受盐，其中R、R1、R2和X如本文所定义。还公开了在治疗癌症、自身免疫、炎症和其他Pim激酶相关疾病中使用这些组合物和方法。
• A new class of pyrazolo[5,1-c][1,2,4]triazines as γ-aminobutyric type A (GABAA) receptor subtype ligand: synthesis and pharmacological evaluation
  作者：Gabriella Guerrini、Giovanna Ciciani、Simona Daniele、Claudia Martini、Camilla Costagli、Chiara Guarino、Silvia Selleri

  DOI：10.1016/j.bmc.2018.04.011

  日期：2018.5

  between compounds with pyrazolo[1,5-a]pyrimidine structure (series 4-6) and pyrazolo[5,1-c][1,2,4]triazine core (series 9) as ligands at GABAA-receptor subtype, was evaluated. Moreover, for pyrazolotriazine derivatives having binding recognition, the interaction on recombinant rat α(1-3,5) GABAA receptor subtypes, was performed. Among these latter, emerge compounds 9c, 9k, 9l, 9m and 9n as α1-selective

  以吡唑并[1,5-a]嘧啶结构（4-6系列）和吡唑并[5,1-c] [1,2,4]三嗪核心（9系列）为配体的化合物在GABAA受体亚型之间的比较，进行了评估。此外，对于具有结合识别的吡唑并三嗪衍生物，进行了对重组大鼠α（1-3,5）GABAA受体亚型的相互作用。在这些化合物中，出现了化合物9c，9k，9l，9m和9n作为α1选择性配体，而9h作为α2选择性配体。
• [EN] HETEROCYCLIC PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE HÉTÉROCYCLIQUES
  申请人：TOLERO PHARMACEUTICALS INC

  公开号：WO2013013188A1

  公开（公告）日：2013-01-24

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一的蛋白激酶（I）、（II）或（III）：或其立体异构体、前药、互变异构体或药用可接受盐，其中R、R1、R2和X如本文所定义。还公开了在治疗癌症、自身免疫、炎症和其他Pim激酶相关疾病中使用这些蛋白激酶的组合物和方法。